E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
An inflammatory, infectious disease caused by the parasite Trypanosoma cruzi |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Parasitic Diseases [C03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008384 |
E.1.2 | Term | Chagas' disease |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the superiority of a 60-day regimen of nifurtimox to historical untreated control at the 12-month follow-up (360 days from end of treatment [EOT]) as seroreduction (defined as a ≥ 20% reduction in optical density [OD] measured by conventional enzyme-linked immune sorbent assay [ELISA]) compared to baseline in subjects ≥8 months to <18 years of age at randomization; or sero-conversion (defined as negative Immunoglobulin G [IgG] concentration) in all subjects |
|
E.2.2 | Secondary objectives of the trial |
- To assess the comparability of a 30-day regimen of nifurtimox to a 60-day regimen of nifurtimox as sero-reduction or sero-conversion at the 12-month follow-up (360 days from EOT) - To evaluate the safety/tolerability profile of nifurtimox by laboratory parameters (hematology, blood chemistry, urinalysis), electrocardiogram (ECG) monitoring, vital sign measurements (blood pressure, heart rate, respiratory rate, temperature), adverse event (AE) monitoring, and physical examinations, including neurological examinations - To evaluate the pharmacokinetics (PK)/pharmacodynamics (PD) of nifurtimox in children receiving the drug for treatment of Chagas’ disease (to be described in a separate report) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Part 1: - Male and female pediatric subjects aged 0 days to younger than 18 years - Chagas’ disease diagnosed/ confirmed by a) Subjects < 8 months of age at randomization must demonstrate direct observation of Trypanosoma cruzi by concentration test; b) Subjects ≥ 8 months to < 18 years of age at randomization must demonstrate a positive conventional ELISA result for both recombinant ELISA and total purified antigen ELISA Part 2: - Male and female subjects who were randomized and received at least one dose of their assigned 60- or 30-day regimen of nifurtimox treatment |
|
E.4 | Principal exclusion criteria |
Part 1: - Subjects aged 0 to 27 days who, at birth, were pre-term, weighed less than 2500 g, or had a maximum Apgar score < 7 at 5 minutes - Subjects with any of the following conditions that is associated with Chagas’ disease, such as: Known evidence of Chagas’ disease-related cardiomyopathy/ Chagas’ heart disease; Known evidence of Chagas’ disease-related gastrointestinal dysfunction (e.g. megaoesophagus, megacolon, or both) or Chagas’ digestive disease; Serious manifestations of acute Chagas’ disease, including myocarditis, meningoencephalitis, or pneumonitis; Known evidence of Chagas’ disease-related damage to the peripheral nervous system or peripheral neuropathy; Clinically significant psychiatric disorder (e.g. moderate to severe depression, severe anxiety, or psychosis) or epilepsy - Subjects with contraindications/ warnings to nifurtimox administration, or with conditions that may increase the risk of the undesirable effects of nifurtimox - Subjects who have had previous treatment with trypanocidal agents or an accepted indication for antiparasitic therapy (e.g. reactivation of Chagas' infection due to immunosuppression by several diseases or treatment with steroids) - Subjects living in housing conditions where there is no active or effective vector-control to Trypanosoma cruzi reinfection as determined by Ministry of Health guidelines in each country Part 2: - Subjects with acute or chronic health conditions or congenital disorders which, in the opinion of the investigator, would make them unsuitable for participation in the clinical study - Subjects living in housing conditions where there is no active or effective vector-control to Trypanosoma cruzi reinfection as determined by Ministry of Health guideline of the respective country - Subjects with clinical manifestations of Chagas’ disease, such as: Known evidence of Chagas’ disease-related gastrointestinal dysfunction; Serious manifestations of acute Chagas’ disease, including myocarditis, meningoencephalitis, or pneumonitis - Immuno-compromised subjects (e.g. those with human immunodeficiency virus infection primary immunodeficiency, or prolonged treatment with corticosteroids or other immunosuppressive drugs) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Percentage of subjects with sero-reduction or sero-conversion - Incidence rate of seronegative conversion for subjects received at least one dose of the 60-day nifurtimox treatment |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- 12 months post-treatment - 48 months post-treatment |
|
E.5.2 | Secondary end point(s) |
Part 1: - Clinical signs/symptoms of Chagas’ disease - Concentration test for Trypanosoma cruzi (subjects < 8 months of age at randomization) - Serological response using non-conventional enzyme-linked immunosorbent assay-F29 (ELISAF29) test - Disease state determined by qPCR - Treatment emergent adverse events and treatment-emergent serious adverse events - Hematology, blood chemistry, coagulation and urinalysis abnormalities - ECG abnormalities - Vital signs - Plasma nifurtimox concentrations Part 2: - Incidence rate of seronegative conversion in subjects who received at least one dose of the 30-day nifurtimox treatment regimen - Proportion of responders who show both seronegative conversion and no evidence of established cardiomyopathy - Serial reduction of optical density |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Part 1: - Up to Visit 11 post-treatment - Up to Visit 9 post-treatment - Up to Visit 11 post-treatment - Up to Visit 11 post-treatment - Up to Visit 11 post-treatment - Up to Visit 11 post-treatment - Up to Visit 11 post-treatment - Up to Visit 11 post-treatment - Pre-dose and up to 8 hours post-dose Part 2: - 48 months post-treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
historical placebo control |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Argentina |
Bolivia, Plurinational State of |
Colombia |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 15 |